Rick Doblin outlines MAPS’ strategy for the development of the therapeutic use of MDMA into an FDA-approved prescription medicine, at the State of Ecstasy conference in San Francisco, sponsored by the Lindesmith Center- Drug Policy Foundation. Additional transcripts of other speakers have been helpfully archived by an anti-drug group.